Department of Otolaryngology-Head & Neck Surgery, Vanderbilt Voice Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232-8605, USA.
Otolaryngol Head Neck Surg. 2011 Feb;144(2):252-6. doi: 10.1177/0194599810391626. Epub 2011 Jan 24.
Recurrent respiratory papillomatosis (RRP) is often described as a benign disease. However, the natural progression of dysplasia and transformation to squamous cell carcinoma has not been elucidated for RRP. This study delineates our extensive experience with dysplasia in RRP.
STUDY DESIGN/SETTING: Case series with chart review.
Demographic data and surgical pathology were analyzed for patients diagnosed with RRP at greater than 18 years of age who underwent operative intervention without cidofovir treatment for RRP between 2004 and 2009.
Fifty-four patients were identified. Dysplasia was identified in 27 of 54 patients (50%). Of the 54 patients, 50% had no dysplasia, 26% had mild dysplasia (grade 1), 11% had moderate dysplasia (grade 2), 4% had severe dysplasia (grade 3), 7% had carcinoma in situ, and 2% had squamous cell carcinoma as the highest documented degree of dysplasia. Thirty of 54 patients (55.6%) had 2 or more operative interventions. Nine of the 30 patients (30%) developed a higher dysplastic grade during the course of treatment. Time to progression averaged 16.2 ± 8.7 months for patients with initially benign disease. Of those patients with dysplasia progression, only 1 of 9 (11.1%) developed squamous cell carcinoma. Patients presenting with benign or mild dysplasia typically did not progress beyond mild dysplasia (22 of 24, 91.7%).
Dysplasia is common in RRP. Progression of dysplasia, especially with an initial dysplastic grading of benign or mild disease, is rare.
复发性呼吸道乳头瘤病(RRP)通常被描述为一种良性疾病。然而,RRP 向不典型增生和鳞状细胞癌转化的自然进程尚未阐明。本研究阐述了我们在 RRP 中不典型增生方面的广泛经验。
研究设计/设置:病例系列,伴有图表回顾。
对 2004 年至 2009 年间因 RRP 大于 18 岁而接受手术干预且未接受西多福韦治疗的患者进行了病例分析,分析了这些患者的人口统计学数据和手术病理学数据。
共确定了 54 例患者。27/54 例(50%)患者存在不典型增生。在 54 例患者中,50%无不典型增生,26%为轻度不典型增生(1 级),11%为中度不典型增生(2 级),4%为重度不典型增生(3 级),7%为原位癌,2%为最高记录的不典型增生程度为鳞状细胞癌。30/54 例(55.6%)患者进行了 2 次或以上的手术干预。30 例患者中有 9 例(30%)在治疗过程中出现了更高的不典型增生分级。最初为良性疾病的患者进展平均时间为 16.2±8.7 个月。在不典型增生进展的患者中,仅有 1/9(11.1%)发展为鳞状细胞癌。具有不典型增生进展的患者,其最初的不典型增生分级为良性或轻度不典型增生(22/24,91.7%)。
不典型增生在 RRP 中很常见。不典型增生的进展,特别是在最初的不典型增生分级为良性或轻度疾病时,较为罕见。